Amylyx Pharmaceuticals (AMLX) Net Equity Issued and Repurchased (2021)
Amylyx Pharmaceuticals' (AMLX) quarterly Net Equity Issued and Repurchased came in at $209000.0 in Q4 2021, down 99.84% quarter-over-quarter from $132.7 million in Q3 2021.
Amylyx Pharmaceuticals (AMLX) Net Equity Issued and Repurchased (2021) Analysis & Trends
Amylyx Pharmaceuticals' Net Equity Issued and Repurchased history runs 1 years deep, the most recent figure standing at $209000.0 for Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 500,000.00 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Amylyx Pharmaceuticals | 1.94 Bn | 1.94 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 209,000.00 |
| Dec 31, 2021 | 209,000.00 |
| Sep 30, 2021 | 132.72 Mn |
| Sep 30, 2021 | 132.72 Mn |